Drug developed bone cancer treatment

Nuclear Medicine and the University of Bonn, Germany, the U.S. Oak Ridge National Laboratory nuclear medical research team has developed a treatment osteocarcinoma new drugs. Preliminary tests show that the drug can extend the survival time of patients with metastatic bone cancer. Primary bone into bone, bone and bone metastases secondary three categories, with the most common bone metastases. Stage cancer patients has been difficult for the treatment of bone metastases. Scientists in Germany and the United States in August issue of the "Clinical Oncology Report" published papers said. Rhenium-188 radioisotope used in the B-1-phosphate (HEDP) into a new drug, it issued the Beta higher energy radiation, but also partially destroyed to contain the spread of cancer tumors Patients also can inhibit the sense of pain. Researchers from 64 prostate cancer patients with bone metastasis from deteriorating into a comparison test, The average time to tumor proliferation of new drugs will be extended from 2.3 to 7 months. The average survival time from 7 months to 12.7 months, and drug side effects. Patients feel pain significantly decreased. Researchers said that there is need for this new drug can be put on a large-scale clinical trial application.